🚀 VC round data is live in beta, check it out!
SpyGlass Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for SpyGlass Pharma and similar public comparables like Geron, Valneva, Center Laboratories, Lumosa Therapeutics and more.
SpyGlass Pharma Overview
About SpyGlass Pharma
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
Founded
2019
HQ
Employees
65
Website
Sectors
Financials (LTM)
EV
$817M
SpyGlass Pharma Financials
SpyGlass Pharma reported last 12-month revenue of — and negative EBITDA of ($44M).
In the same LTM period, SpyGlass Pharma generated — in gross profit, ($44M) in EBITDA losses, and had net loss of ($44M).
SpyGlass Pharma P&L
In the most recent fiscal year, SpyGlass Pharma reported revenue of — and EBITDA of ($41M).
SpyGlass Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($44M) | XXX | ($41M) | XXX | XXX | XXX |
| Net Profit | ($44M) | XXX | ($40M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
SpyGlass Pharma Stock Performance
SpyGlass Pharma has current market cap of $931M, and enterprise value of $817M.
SpyGlass Pharma's stock price is $27.95.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $817M | $931M | 0.0% | XXX | XXX | XXX | $-1.20 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSpyGlass Pharma Valuation Multiples
SpyGlass Pharma trades at (18.4x) EV/EBITDA.
SpyGlass Pharma Financial Valuation Multiples
As of March 29, 2026, SpyGlass Pharma has market cap of $931M and EV of $817M.
Equity research analysts estimate SpyGlass Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SpyGlass Pharma has a P/E ratio of (21.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $931M | XXX | $931M | XXX | XXX | XXX |
| EV (current) | $817M | XXX | $817M | XXX | XXX | XXX |
| EV/EBITDA | (18.4x) | XXX | (20.0x) | XXX | XXX | XXX |
| EV/EBIT | (17.7x) | XXX | (19.7x) | XXX | XXX | XXX |
| P/E | (21.0x) | XXX | (23.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (24.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified SpyGlass Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
SpyGlass Pharma Margins & Growth Rates
SpyGlass Pharma's revenue in the last fiscal year grew by —.
SpyGlass Pharma's revenue per employee in the last FY averaged $0.0M.
SpyGlass Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 27% | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
SpyGlass Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Geron | XXX | XXX | XXX | XXX | XXX | XXX |
| Valneva | XXX | XXX | XXX | XXX | XXX | XXX |
| Center Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| Lumosa Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Bicara Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SpyGlass Pharma M&A Activity
SpyGlass Pharma acquired XXX companies to date.
Last acquisition by SpyGlass Pharma was on XXXXXXXX, XXXXX. SpyGlass Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by SpyGlass Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSpyGlass Pharma Investment Activity
SpyGlass Pharma invested in XXX companies to date.
SpyGlass Pharma made its latest investment on XXXXXXXX, XXXXX. SpyGlass Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by SpyGlass Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout SpyGlass Pharma
| When was SpyGlass Pharma founded? | SpyGlass Pharma was founded in 2019. |
| Where is SpyGlass Pharma headquartered? | SpyGlass Pharma is headquartered in United States. |
| How many employees does SpyGlass Pharma have? | As of today, SpyGlass Pharma has over 65 employees. |
| Is SpyGlass Pharma publicly listed? | Yes, SpyGlass Pharma is a public company listed on Nasdaq. |
| What is the stock symbol of SpyGlass Pharma? | SpyGlass Pharma trades under SGP ticker. |
| When did SpyGlass Pharma go public? | SpyGlass Pharma went public in 2026. |
| Who are competitors of SpyGlass Pharma? | SpyGlass Pharma main competitors are Geron, Valneva, Center Laboratories, Lumosa Therapeutics. |
| What is the current market cap of SpyGlass Pharma? | SpyGlass Pharma's current market cap is $931M. |
| Is SpyGlass Pharma profitable? | No, SpyGlass Pharma is not profitable. |
| What is the current EBITDA of SpyGlass Pharma? | SpyGlass Pharma has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of SpyGlass Pharma? | Current EBITDA multiple of SpyGlass Pharma is (18.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.